Novo Nordisk presented data from a phase 2 trial evaluating the safety, pharmacokinetics and efficacy of a recombinant factor VIIa (rFVIIa) analogue, designed to have a faster action profile than NovoSeven® (rFVIIa) in haemophilia patients with inhibitors (antibody formation against factor preparations).

Pfizer Inc. (NYSE: PFE) announced that a significantly higher proportion of patients with newly diagnosed chronic myeloid leukemia who were treated with bosutinib (39 percent) experienced a major molecular response (MMR), a secondary endpoint, compared with patients treated with imatinib (26 percent) in the intent-to-treat (ITT) population (p=0.002).

China is set to become the world's powerhouse of innovation over the next decade, eclipsing the United States and Japan, according to an international survey released by AstraZeneca. The world's most populous nation and second largest economy will also be its most inventive by 2020, followed by India, the AstraZeneca Innovation Survey shows.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive data from a Phase III study of Rituxan/MabThera (rituximab) in patients with advanced follicular lymphoma who did not have symptoms of disease (asymptomatic disease).

Amgen Inc. (Nasdaq: AMGN) announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate(R) (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP).

With more than 170 presentations focused on its marketed and pipeline compounds at key oncology medical congresses in December, Novartis continues to demonstrate progress of its innovative research and development efforts, collaboration with the scientific community and commitment to patients with cancer and rare diseases[1],[2].

Genzyme Corporation (Nasdaq: GENZ) has completed the sale of Genzyme Genetics to Laboratory Corporation of America Holdings (NYSE: LH) for $925 million in cash. Under the final terms of the agreement, LabCorp purchased substantially all of the assets of the Genzyme Genetics business, including testing services, technology,